Business ❯ Healthcare

Pharmaceuticals

Drug Development Clinical Trials Market Competition Weight Loss Drugs Drug Pricing Biotechnology Manufacturing Acquisitions Market Trends Oncology

Hims & Hers Soars as Novo Nordisk Reinstates Supply Deal for Ozempic and Wegovy

Novo's withdrawal of its lawsuit clears a key risk, prompting fresh analyst upgrades.

Guardian Pharmacy Lifts 2026 EBITDA Outlook After Strong 2025, Warns of 2027 IRA Hit

Novo Nordisk Strikes Deal With Hims & Hers to Sell Wegovy and Ozempic, Drops Lawsuit

Eli Lilly to Invest $3 Billion in China to Build Orforglipron Manufacturing

C-Further Launches First Pediatric Cancer Programs, Taps MiNK for PRAME iNKT Therapy

Novo Nordisk Extends Weight‑Loss Lead as Amgen’s Once‑Monthly MariTide Reaches Phase 3

Novo Nordisk Invests €432 Million to Expand Athlone Plant for Oral GLP-1 Tablets

Collegium Reports Record 2025 Results, Projects Strong 2026 for Jornay as Hikma Generic Nears

Novartis to Build 46,000‑Square‑Foot Radioligand Therapy Plant in Denton, Texas

Novo Nordisk to Cut U.S. List Prices for Wegovy, Ozempic and Rybelsus to $675 in 2027

GSK to Acquire 35Pharma for $950 Million to Add Pulmonary Hypertension Candidate HS235

FDA to Review Moderna’s Flu Shot as Shares Rally on Earnings Beat

Novo’s CagriSema Falls Short of Lilly’s Tirzepatide in 84-Week Head‑to‑Head Trial

Serena Williams Reinstated by ITIA, Now Eligible to Compete Again

Gilead to Acquire Arcellx for Up to $7.8 Billion to Gain Full Control of CAR-T Anito-Cel

Pritzker’s Budget Boosts School Aid but Stops Short of Full Formula Funding, Prompting Union Criticism

Telix Confirms Webcast Investor Sessions at Oppenheimer and TD Cowen Conferences

Insmed Sets $1 Billion 2026 Brinsupri Target After Strong First Full Quarter

Johnson & Johnson to Build $1 Billion Cell Therapy Plant in Pennsylvania

Vistagen Investors Face March 16 Lead‑Plaintiff Deadline as Law Firms Seek Clients